ImmunityBio (IBRX) Non-Current Assets (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Non-Current Assets data on file, last reported at $193.7 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $193.7 million, changed 0.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $764.1 million (down 3.99% YoY), and the FY2025 annual result was $187.0 million, down 5.71% from the prior year.
• Non-Current Assets advanced to $193.7 million in Q1 2026 per IBRX's latest filing, from $187.0 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $229.9 million in Q1 2023 and troughed at $177.2 million in Q1 2022.
• A 5-year average of $203.4 million and a median of $201.5 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 74.92% in 2022, then slipped 10.85% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $221.8 million in 2022, then decreased by 5.15% to $210.4 million in 2023, then dropped by 5.71% to $198.3 million in 2024, then dropped by 5.71% to $187.0 million in 2025, then advanced by 3.56% to $193.7 million in 2026.
• Business Quant data shows IBRX's Non-Current Assets at $193.7 million in Q1 2026, $187.0 million in Q4 2025, and $189.5 million in Q3 2025.